ATAI Life Sciences NV (XETRA:9VC) — Market Cap & Net Worth
Market Cap & Net Worth: ATAI Life Sciences NV (9VC)
ATAI Life Sciences NV (XETRA:9VC) has a market capitalization of $1.27 Billion (€1.09 Billion) as of June 19, 2026. Listed on the XETRA stock exchange, this Germany-based company holds position #8023 globally and #1059 in its home market, demonstrating a -2.89% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ATAI Life Sciences NV's stock price €3.43 by its total outstanding shares 363214602 (363.21 Million). Review 9VC liabilities breakdown to assess the company's total debt and financial obligations.
ATAI Life Sciences NV Market Cap History: 2021 to 2025
ATAI Life Sciences NV's market capitalization history from 2021 to 2025. Data shows change from $2.75 Billion to $1.45 Billion (-24.16% CAGR).
ATAI Life Sciences NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ATAI Life Sciences NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1685.45x
ATAI Life Sciences NV's market cap is 1685.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.75 Billion | $20.38 Million | -$167.81 Million | 135.04x | N/A |
| 2022 | $985.16 Million | $233.00K | -$152.38 Million | 4228.14x | N/A |
| 2023 | $588.55 Million | $314.00K | -$40.22 Million | 1874.35x | N/A |
| 2024 | $519.12 Million | $308.00K | -$149.27 Million | 1685.45x | N/A |
Competitor Companies of 9VC by Market Capitalization
Companies near ATAI Life Sciences NV in the global market cap rankings as of June 19, 2026.
Key companies related to ATAI Life Sciences NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
ATAI Life Sciences NV Historical Marketcap From 2021 to 2025
Between 2021 and today, ATAI Life Sciences NV's market cap moved from $2.75 Billion to $ 1.45 Billion, with a yearly change of -24.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €1.45 Billion | +180.25% |
| 2024 | €519.12 Million | -11.80% |
| 2023 | €588.55 Million | -40.26% |
| 2022 | €985.16 Million | -64.20% |
| 2021 | €2.75 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of ATAI Life Sciences NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.27 Billion USD |
| MoneyControl | $1.27 Billion USD |
| MarketWatch | $1.27 Billion USD |
| marketcap.company | $1.27 Billion USD |
| Reuters | $1.27 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ATAI Life Sciences NV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more